Company
Headquarters: Seoul, South Korea
Employees: 507
CEO: Ms. Soon-Ock Jung
₩245.04 Billion
KRW as of Jan. 1, 2025
US$166.7 Million
Company | Market Cap (USD) |
---|---|
Lilly | $689.42 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $487.54 B |
Johnson & Johnson | $353.05 B |
AbbVie | $301.60 B |
REYON Pharmaceutical Co., Ltd. manufactures and sells finished medicines and APIs in South Korea and internationally. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
REYON Pharmaceutical Co. Ltd has the following listings and related stock indices.
Stock: KRX: 102460 wb_incandescent